A phase I clinical study of IC-100
Latest Information Update: 03 Apr 2025
At a glance
- Drugs IC 100 ZyVersa Therapeutics (Primary)
- Indications Adult respiratory distress syndrome; Alzheimer's disease; Autoimmune disorders; Metabolic disorders; Neurodegenerative disorders
- Focus Adverse reactions
Most Recent Events
- 27 Mar 2025 According to a ZyVersa Therapeutics media release, Investigational New Drug Application (IND) for IC 100 is anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweight subjects.
- 03 Jan 2024 According to a ZyVersa Therapeutics media release, the IC 100 preclinical program is nearing completion and IND submission is planned for the fourth quarter of 2024, with Phase 1 trial initiation expected shortly thereafter.
- 13 Jun 2023 According to a ZyVersa Therapeutics media release, the company expects file an IND to initiate a Phase 1 trial in early 2024.